| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration agreement revenue | 0 | 0 | - | - |
| Research and development | 936 | 1,368 | 1,530 | 931 |
| Selling, general and administrative | 552 | 683 | 1,196 | 825 |
| Total costs and expenses | 1,488 | 2,051 | 2,726 | 1,756 |
| Operating loss | -1,488 | -2,051 | -2,726 | -1,756 |
| Total other income, net | 5 | 2 | 14 | 19 |
| Net loss | -1,483 | -2,049 | -2,712 | -1,737 |
| Net loss per share, basic and diluted (in dollars per share) | -0.24 | -0.4 | -0.59 | -0.61 |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 6,277,848 | 5,059,736 | 4,635,764 | 2,827,492 |
BioCardia, Inc. (BCDA)
BioCardia, Inc. (BCDA)